secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001708599-25-000126
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease
--------------------------------------------------------------------------------

- FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.
- Serina expects formal clinical-hold letter within 30 days and will work expeditiously with FDA to address requests.
- FDA previously indicated support for SER-252 development under 505(b)(2) NDA pathway; CEO remains confident in program.
- SER-252 is Serina's lead program for advanced Parkinson's; Phase 1b trial designed as randomized, double-blind, placebo-controlled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000126/0001708599-25-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000126/ser-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer